Nick Pavlakis

16.1k total citations · 2 hit papers
307 papers, 8.6k citations indexed

About

Nick Pavlakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Nick Pavlakis has authored 307 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Oncology, 170 papers in Pulmonary and Respiratory Medicine and 58 papers in Epidemiology. Recurrent topics in Nick Pavlakis's work include Lung Cancer Treatments and Mutations (82 papers), Colorectal Cancer Treatments and Studies (66 papers) and Lung Cancer Research Studies (64 papers). Nick Pavlakis is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Colorectal Cancer Treatments and Studies (66 papers) and Lung Cancer Research Studies (64 papers). Nick Pavlakis collaborates with scholars based in Australia, United States and United Kingdom. Nick Pavlakis's co-authors include Stephen Clarke, Martin R. Stockler, Nico van Zandwijk, Michael Boyer, Steven Kao, Matthew H. Wong, Anthony J. Gill, Ross Davey, Britta Stordal and Janette L. Vardy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Nick Pavlakis

298 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

2017 539 citations Nick Pavlakis, Michael Boyer et al. profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations Solange Peters, Tony Mok et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nick Pavlakis Australia	45	4.9k	3.5k	1.9k	1.6k	995	307	8.6k
Zhengjia Chen United States	51	3.1k 0.6×	2.5k 0.7×	2.4k 1.2×	989 0.6×	1.2k 1.2×	267	8.3k
Rossana Berardi Italy	45	4.2k 0.8×	2.8k 0.8×	1.9k 1.0×	1.4k 0.9×	1.1k 1.1×	344	7.4k
Emanuela Scarpi Italy	46	3.5k 0.7×	1.8k 0.5×	1.2k 0.6×	1.4k 0.9×	886 0.9×	265	7.0k
Nipun B. Merchant United States	48	5.0k 1.0×	2.0k 0.6×	1.7k 0.9×	1.1k 0.7×	2.1k 2.1×	212	7.7k
Nasser H. Hanna United States	50	7.0k 1.4×	7.1k 2.0×	2.7k 1.4×	1.1k 0.7×	1.4k 1.4×	301	11.4k
Óscar Arrieta Mexico	48	3.7k 0.8×	3.2k 0.9×	2.3k 1.2×	1.5k 0.9×	610 0.6×	390	8.4k
Massimo Di Maïo Italy	50	5.1k 1.0×	3.9k 1.1×	2.0k 1.0×	1.4k 0.9×	1.1k 1.1×	403	9.3k
Bert H. O’Neil United States	47	5.7k 1.2×	2.0k 0.6×	2.5k 1.3×	1.3k 0.8×	1.4k 1.4×	255	9.1k
Daniel Hochhauser United Kingdom	43	4.5k 0.9×	1.4k 0.4×	2.7k 1.4×	1.5k 1.0×	1.0k 1.0×	153	7.4k
Muhammad Wasif Saif United States	44	4.6k 0.9×	1.4k 0.4×	1.9k 1.0×	889 0.6×	1.2k 1.2×	412	7.9k

Countries citing papers authored by Nick Pavlakis

Since Specialization

Citations

This map shows the geographic impact of Nick Pavlakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Pavlakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Pavlakis more than expected).

Fields of papers citing papers by Nick Pavlakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Pavlakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Pavlakis. The network helps show where Nick Pavlakis may publish in the future.

Co-authorship network of co-authors of Nick Pavlakis

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Pavlakis. A scholar is included among the top collaborators of Nick Pavlakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Pavlakis. Nick Pavlakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cooper, Wendy A., Caroline Cooper, Stephen B. Fox, et al.. (2025). Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia. Pathology. 57(4). 425–436. 1 indexed citations

Jänne, Pasi A., Bin-Chao Wang, Byoung Chul Cho, et al.. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology. 43(13). 1553–1563. 7 indexed citations

Fantoni, A, Lydia Warburton, Benjamin Solomon, et al.. (2024). Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT). Clinical Lung Cancer. 25(5). 449–459.

Gill, Anthony J., et al.. (2024). National screening for colorectal cancer is associated with stage shift to earlier diagnosis. ANZ Journal of Surgery. 94(7-8). 1279–1285. 1 indexed citations

Pavlakis, Nick, Malinda Itchins, Jennifer Arena, et al.. (2023). The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer. Journal of Clinical Medicine. 12(5). 1989–1989. 24 indexed citations

Gough, Karla, Allison Drosdowsky, Timothy Price, et al.. (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer. 31(10). 577–577. 1 indexed citations

Leck, Lionel, Patric J. Jansson, Nick Pavlakis, et al.. (2022). Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Cancers. 14(14). 3528–3528. 24 indexed citations

Luk, Ian Y., Laura J. Jenkins, Andrew Martin, et al.. (2021). Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. Molecular Cancer Therapeutics. 20(4). 704–715. 14 indexed citations

Grothey, Axel, Jean‐Yves Blay, Nick Pavlakis, Takayuki Yoshino, & Jordi Bruix. (2020). Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews. 86. 101993–101993. 82 indexed citations

10.

Hicks, Rodney J., Nick Pavlakis, Emma Link, et al.. (2020). The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸F) positron‐emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology. 16(3). 150–157. 2 indexed citations

11.

Gough, Karla, Allison Drosdowsky, Timothy Price, et al.. (2019). Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols. 8(12). e14361–e14361. 3 indexed citations

12.

Crumbaker, Megan, Alexander Guminski, Howard Gurney, et al.. (2017). Real‐world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. Asia-Pacific Journal of Clinical Oncology. 14(2). e45–e49. 5 indexed citations

13.

Hoersch, Dieter, Michael Kulke, Emily K. Bergsland, et al.. (2016). Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome. Neuroendocrinology. 103. 89–89. 1 indexed citations

14.

Anthony, Lowell, Dieter Hoersch, Matthew H. Kulke, et al.. (2016). Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome : Patient Exit Interviews. Pancreas. 45(3). 470–470. 1 indexed citations

15.

Pavlakis, Nick, et al.. (2015). Rare molecular subsets among lung tumours - what makes them stand apart from the common?. Cancer Forum. 39(1). 35.

16.

Hudson, Amanda L., et al.. (2014). Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines. Cancer Immunology Research. 2(5). 469–479. 20 indexed citations

17.

Wong, Matthew H., Aiqun Xue, Sohel M. Julovi, et al.. (2014). Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 20(15). 4047–4058. 33 indexed citations

18.

Khasraw, Mustafa, et al.. (2013). THE ADDITION OF ANTI-ANGIOGENIC TYROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS. Deakin Research Online (Deakin University). 1 indexed citations

19.

Lee, Brian Y., David A. Brown, Mark P. Molloy, et al.. (2009). Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research. 69(19). 7696–7703. 86 indexed citations

20.

Christie, David, Elías Gracia, M. Gospodarowicz, et al.. (2007). Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group. Haematologica. 92. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact